relapse. In Gajdos,4 Ippoliti5 and for part of Cosi's8 series, the patients were treated with IVIg in a static phase of the disease that lasted from two to six months. There was no significant difference in improvement between chronic-static and acute cases, as improvement was observed in more than 70% of both groups. In the responding patients, there was 
The immediate adverse side effects of IVIg in these series were limited to minor symptoms such as, headaches, pedal oedema, or mild dyspnoea. These effects were seen in less than 10% of patients and it was not necessary to interrupt their treatment. Aseptic meningitis has recently been reported as a complication of IVIg therapy in the treatment of myasthenia gravis."
Since 1988, we have treated some of our MG patients with IVIg. We have retrospectively selected 10 patients (seven men, three women, median age 53, two of them with thymoma) who were treated at an early stage of the disease (median six months), and who were not taking concomittant immunological medication. We observed similar responses to previous authors for this homogenous group of patients. Seven of 10 patients showed marked improvement, which occurred rapidly within one week and lasted for six to 12 weeks whether the patient was in an acute or stationary phase of the disease.
Our experience enables us to put forward some positive and negative aspects of IVIg treatment in MG. The negative aspects include: the temporary nature of the response, the high cost of the product, and the injection of human blood and the accompanying risk of infection. However, the positive impact of IVIg therapy on MG are evident in the high rate of response, rapid onset of improvement, the lack of recognised short-and long-term toxicity, the reproducibility of the response (the temporary nature of response may be overcome by using repetitive courses) resulting in the reduction of corticosteroid therapy in the majority of patients.
The 
